08 Nov SAHPRAs position on GLP1 and GIP-GLP1 products that are compounded, substandard and falsified Pretoria, 08 November 2024 The South African Health Products Regulatory Authority (SAHPRA) is concerned about the proliferation of falsified, compounded and substandard Glucagon-like Peptide (GLP-1)-containing products being made available to the public via websites, social media platforms and other informal channels
Under a simulation model, even a narrow expansion of coverage for GLP-1s comes at a cost because the prices are so high
These GLP-1 receptor agonists signal to the brain that you are full, slow down digestion, and help stabilize blood sugar levels
Glutathione has been shown to influence these signaling pathways, potentially encouraging a more balanced and less aggressive immune response
Gallbladder and biliary tract events have been reported with GLP-1-based therapies, primarily related to gallstones